4/A: 180 Life Sciences Director Amends Equity Award Filing, Details Restricted Stock and Option Grants

180 Life Sciences Corp. Director Ryan Smith filed an amended Form 4 detailing the acquisition of 102,181 restricted common shares and 255,000 non-qualified stock options, with vesting tied to continued service and option exercise contingent on stockholder approval.

Summary

• Ryan Lewis Smith, a Director of 180 Life Sciences Corp. (ATNF), filed an amended Form 4 (Form 4/A) on June 30, 2025.
• The amendment was filed to reflect a retroactive adjustment made by the Board of Directors and Compensation Committee on June 28, 2025, to ensure sufficient room under the Equity Plan for the awards granted to Smith and other awards made on the same date.
• On June 17, 2025, Smith acquired 102,181 shares of Common Stock. These are restricted stock shares subject to time-based vesting, with 50% vesting on December 17, 2025, and the remaining 50% on June 17, 2026, contingent on his continued service to the Issuer. These shares were issued under the Issuer's 2022 Equity Compensation Plan.
• On the same date, Smith also acquired 255,000 non-qualified stock options with an exercise price of $0.929. These options vest 50% on December 17, 2025, and the remaining 50% on June 17, 2026, subject to his continued service.
• The options were issued under the Issuer's 2025 Option Incentive Plan, which is subject to stockholder approval. Options cannot be exercised prior to obtaining stockholder approval and will be cancelled if approval is not obtained. The options expire on June 17, 2035.
• Both the restricted stock and options were granted to Smith in consideration for services rendered and agreed to be rendered as a member of the Board of Directors.
• Following these reported transactions, Smith beneficially owns 167,181 shares of Common Stock and 255,000 derivative securities (options).

Sentiment

Score: 6

Explanation: The filing is largely administrative, detailing standard equity compensation for a director. The positive is the alignment of interests, but the contingency of options on stockholder approval introduces a minor uncertainty, preventing a higher score. It's a neutral to slightly positive event.

Positives

• The equity awards align the director's financial interests with the long-term performance and shareholder value of 180 Life Sciences Corp.
• The vesting schedule for both restricted stock and options incentivizes the continued service and retention of a key board member, Ryan Smith.

Negatives

• The 255,000 non-qualified stock options granted are contingent on stockholder approval of the 2025 Option Incentive Plan; if approval is not obtained, these options will be cancelled.

Risks

• The 255,000 stock options granted to Director Ryan Smith face the risk of cancellation if the 2025 Option Incentive Plan does not receive stockholder approval.
• The vesting of both the 102,181 restricted stock shares and the 255,000 stock options is contingent on Ryan Smith's continued service to 180 Life Sciences Corp. through the vesting dates.

Future Outlook

The future outlook for the 255,000 non-qualified stock options is contingent on obtaining stockholder approval for the 2025 Option Incentive Plan. If approval is not secured, these options will be cancelled. The vesting of both restricted stock and options is tied to the director's continued service through June 2026, providing a clear incentive for long-term commitment.

Management Comments

• The number of shares awarded to the Reporting Person was retroactively adjusted by the Board of Directors and Compensation Committee of the Company on June 28, 2025, so that there was sufficient room for such award, and other awards made on the same date, under the Equity Plan.
• The options vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer.
• The 2025 Option Incentive Plan is subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for such plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained.

Industry Context

This filing is a routine disclosure of insider equity transactions, common in the biotechnology or pharmaceutical industry for retaining key talent and aligning management incentives with long-term company performance. The reliance on equity compensation plans, subject to shareholder approval, is a standard practice for early-stage or growth companies like 180 Life Sciences Corp. to manage cash burn while incentivizing leadership.

Comparison to Industry Standards

• The use of restricted stock and stock options for director compensation is a standard practice across various industries, including biotechnology, to align director interests with shareholder value.
• The vesting schedule, with half vesting in approximately six months and the remainder in a year, is typical for retaining board members over a medium-term horizon.
• The requirement for stockholder approval for new equity incentive plans, such as the 2025 Option Incentive Plan, is a common corporate governance safeguard, ensuring shareholder oversight of dilution and compensation practices.
• The retroactive adjustment of awards to ensure compliance with existing equity plans is an internal administrative correction, not uncommon, but highlights the need for careful plan management.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution from the issuance of new equity awards, but also benefit from the alignment of director incentives with long-term company performance. The approval of the 2025 Option Incentive Plan will directly impact shareholders' control over equity compensation.
• Employees (specifically Ryan Smith as a director): Receives significant equity compensation, which serves as a strong incentive for continued service and performance within the company.

Next Steps

• Stockholders of 180 Life Sciences Corp. will need to vote on the approval of the 2025 Option Incentive Plan.
• Ryan Smith's restricted stock and options will continue to vest on December 17, 2025, and June 17, 2026, subject to his continued service to the Issuer.

Key Dates

Recommendation

Keywords

180 Life Sciences Corp., ATNF, Form 4/A, Beneficial Ownership, Director Compensation, Equity Awards, Restricted Stock, Stock Options, Stockholder Approval, Corporate Governance, Insider Trading, SEC Filing